<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146493</url>
  </required_header>
  <id_info>
    <org_study_id>4-2957/2017</org_study_id>
    <nct_id>NCT04146493</nct_id>
  </id_info>
  <brief_title>Heparin-Binding Protein and Heparins</brief_title>
  <acronym>HepHep</acronym>
  <official_title>Heparin-binding Protein and Heparins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halla Halldorsdottir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin-Binding protein is a protein from primary and secretory granluae of white blood
      cells. It is released when white blood cells become activated and has been advocated as a
      biomarker for sepsis. The aim of this study is to find out if Heparins in clinical doses can
      change the level of Heparin-binding protein in plasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples are taken from patients before and after Heparins in clinical doses. The
      effects of heparins on Heparin-binding protein concentration in plasma is measured. This is a
      small observational study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the level of Heparin-binding protein</measure>
    <time_frame>Repeated blood sampling during minimum of 1 hour and maximum of 5 hours after given heparin</time_frame>
    <description>Blood samples are taken before and after given heparin</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vascular Disease, Peripheral</condition>
  <condition>Thromboprophylaxis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Vascular surgery group</arm_group_label>
    <description>Patients which are given unfractionated heparin during their vascular surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thromboprophylaxis group</arm_group_label>
    <description>Patients which are given low molecular heparins as a thrombosprofylax after major surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiothoracic surgery</arm_group_label>
    <description>Patients which are given high dose unfractionated heparin during their open heart surgey</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples for Heparin-binding protein measurement</intervention_name>
    <description>Blood samples before and after given heparin</description>
    <arm_group_label>Cardiothoracic surgery</arm_group_label>
    <arm_group_label>Thromboprophylaxis group</arm_group_label>
    <arm_group_label>Vascular surgery group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma which could theoretically contain DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A) Patients operated for peripheral vascular disease or aortic disease B) Patients operated
        for major surgery C) Patients operated for open heart surgery with cardiopulmonary bypass.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned endovascular treatment of aortic aneurysm or peripheral vascular surgery where
             unfractionated heparin in &gt;3000 units are given perioperatively

          -  Planned subcutaneous low molecular weight heparin as a thromboprophylactic treatment
             after major surgery or on Intensive Care treated patients.

          -  Planned open heart surgery with cardiopulmonary bypass.

        Exclusion Criteria:

          -  Under 18 years

          -  Unable to get informed consent from patient or relative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halla Halldorsdottir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Halla D Halldorsdottir, MD</last_name>
    <phone>0046(0)73 063 4080</phone>
    <email>halla.halldorsdottir@sll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Halla Halldorsdottir</name>
      <address>
        <city>Stockholm</city>
        <state>Solna</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halla Halldorsdottir, MD</last_name>
      <phone>0046730634080</phone>
      <email>halla.halldorsdottir@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Eddie Weitzberg, Professor</last_name>
      <phone>0046851770000</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Halla Halldorsdottir</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Heparin-binding protein</keyword>
  <keyword>Heparin</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

